Join
Live feed
·
PRReleasevia Quantisnow
Alector Inc. logo

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

ByQuantisnow·Wall Street's wire, on your screen.
ALEC· Alector Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALEC (Alector Inc.) and more on Quantisnow.